ThirtyFiveBio
Stuart Hughes is currently the CEO of Pathios Therapeutics and the Co-founder of ThirtyFiveBio. Prior to their current roles, Stuart held various positions at Vertex Pharmaceuticals and Eli Lilly. With a background in neuroscience and electrical & electronic engineering, Stuart's career includes research and academic roles at Cardiff University, as well as experience in the pharmaceutical and systems analysis industries.
ThirtyFiveBio
ThirtyFiveBio is an early-stage drug discovery company that was established in 2021 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of GPR35. We are currently engaged in a fully enabled drug discovery program to identify novel small-molecule modulators of GPR35